The genetic testing market accounted for $ 12,682 million in 2019, and is expected to reach $ 21,260 million by 2027, registering a CAGR of 10.1% from 2020 to 2027.
Genetic testing is the study of DNA that identifies gene mutation associated with a variety of genetic disorders. There are various types of genetic testing and several methods such as cytogenetic testing, biochemical testing, molecular testing, and chromosome analysis used to determine changes in a person’s chromosomes, genes, or proteins. The results of a genetic tests confirm or diagnose a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder.
Genetic testing plays a vital role in determining the risk of developing certain diseases as well as screening and sometimes medical treatment. Different types of genetic testing are done for different reasons such as presymptomatic and predictive testing, carrier testing, prenatal testing, and newborn screening.
The global genetic testing market is expected to register substantial growth in the future, owing to rise in incidences of genetic disorders and cancer and rise in awareness & acceptance of personalized medicines. For instance, Genetic testing has been widely used in pharmacogenomics, also referred as drug-gene testing. In addition, advancements in genetic testing techniques are expected to boost the market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the market growth during the forecast period. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players. For instance, Healthcare systems in developing countries such as Brazil, India, and China have experienced significant increase in investments in healthcare and infrastructure which leads to surge in demand for genetic testing in the region.
The global genetic testing market is segmented on the basis of type, technology, application, and region. By type, the market is categorized into predictive & presymptomatic testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. On the basis of technology, it is divided into cytogenetic testing/chromosomal analysis, biochemical testing, and molecular testing. Molecular testing is further classified into DNA sequencing and others. By application, it is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. By region, the genetic testing market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The major players in the genetic testing market are Abbott Laboratories, Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), Myriad Genetics, Inc. (Myriad RBM, Inc.), Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd., Eurofins Scientific, Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., and CSL Ltd.
By Type
By Technology
By Application
By Region
Genetic testing is the study of DNA that identifies gene mutation associated with a variety of genetic disorders. There are various types of genetic testing and several methods such as cytogenetic testing, biochemical testing, molecular testing, and chromosome analysis used to determine changes in a person’s chromosomes, genes, or proteins. The results of a genetic tests confirm or diagnose a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder.
Genetic testing plays a vital role in determining the risk of developing certain diseases as well as screening and sometimes medical treatment. Different types of genetic testing are done for different reasons such as presymptomatic and predictive testing, carrier testing, prenatal testing, and newborn screening.
The global genetic testing market is expected to register substantial growth in the future, owing to rise in incidences of genetic disorders and cancer and rise in awareness & acceptance of personalized medicines. For instance, Genetic testing has been widely used in pharmacogenomics, also referred as drug-gene testing. In addition, advancements in genetic testing techniques are expected to boost the market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the market growth during the forecast period. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players. For instance, Healthcare systems in developing countries such as Brazil, India, and China have experienced significant increase in investments in healthcare and infrastructure which leads to surge in demand for genetic testing in the region.
The global genetic testing market is segmented on the basis of type, technology, application, and region. By type, the market is categorized into predictive & presymptomatic testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. On the basis of technology, it is divided into cytogenetic testing/chromosomal analysis, biochemical testing, and molecular testing. Molecular testing is further classified into DNA sequencing and others. By application, it is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. By region, the genetic testing market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The major players in the genetic testing market are Abbott Laboratories, Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), Myriad Genetics, Inc. (Myriad RBM, Inc.), Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd., Eurofins Scientific, Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., and CSL Ltd.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global negative pressure wound therapy devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Type
- Predictive & Presymptomatic Testing
- Carrier Testing
- Prenatal & Newborn Testing
- Diagnostic Testing
- Pharmacogenomic Testing
- Others
By Technology
- Cytogenetic Testing
- Biochemical Testing
- Molecular Testing
By Application
- Cancer diagnosis
- Genetic Disease Diagnosis
- Cardiovascular Disease Diagnosis
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT:
- Abbott Laboratories
- Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.)
- Myriad Genetics, Inc. (Myriad RBM, Inc.)
- Danaher Corporation (Cepheid)
- F. Hoffmann-La Roche Ltd.
- Eurofins Scientific
- Illumina, Inc.
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- CSL Ltd.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request:
- PerkinElmer, Inc.
- Natera
- Sonic Healthcare
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in adoption of genome editing applications.
3.5.1.2. Rise in prevalence of cancer & other genetic disorders
3.5.1.3. Continuous technological advancements in gene-editing tools
3.5.1.4. Availability of government funding & growth in the number of genomics projects
3.5.2. Restraint
3.5.2.1. Ethical Issues Associated with Genome Editing
3.5.3. Opportunity
3.5.3.1. Presence of key players in emerging economies and applications in several drug discovery processes
3.5.4. Impact analysis
3.6. COVID-19 Impact analysis on the genome editing market
CHAPTER 4: GENOME EDITING MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Cell line engineering
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Genetic engineering
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Gene-modified cell therapy and Diagnostics
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Drug discovery
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Other applications
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
CHAPTER 5: GENOME EDITING MARKET, BY TECHNOLOGY
5.1. Overview
5.1.1. Market size and forecast
5.2. CRISPR
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.2.3. Market size and forecast, by type
5.2.4. Academics & Government Institutes
5.2.4.1. Market size and forecast
5.2.5. Biotechnology & pharma companies
5.2.5.1. Market size and forecast
5.2.6. Contract research organizations
5.2.6.1. Market size and forecast
5.3. TALEN
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.3.3. Market size and forecast, by type
5.3.4. Academics & Government Institutes
5.3.4.1. Market size and forecast
5.3.5. Biotechnology & pharma companies
5.3.5.1. Market size and forecast
5.3.6. Contract research organization
5.3.6.1. Market size and forecast
5.4. ZFN
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.4.3. Market size and forecast, by type
5.4.4. Academics & Government Institutes
5.4.4.1. Market size and forecast
5.4.5. Biotechnology & Pharma Companies
5.4.5.1. Market size and forecast
5.4.6. Contract Research Organizations
5.4.6.1. Market size and forecast
5.5. Other technologies
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.5.3. Market size and forecast, by type
5.5.4. Academics & Government Institutes
5.5.4.1. Market size and forecast
5.5.5. Biotechnology & Pharma Companies
5.5.5.1. Market size and forecast
5.5.6. Contract research organizations
5.5.6.1. Market size and forecast
CHAPTER 6: GENOME EDITING MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Academics & government institutes
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Biotechnology & pharma companies
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Contract Research Organization
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: GENOME EDITING MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U. S. genome editing market, by application
7.2.2.2. U. S. genome editing market, by technology
7.2.2.3. U. S. genome editing market, by end user
7.2.2.4. Canada genome editing market, by application
7.2.2.5. Canada genome editing market, by technology
7.2.2.6. Canada genome editing market, by end user
7.2.2.7. Mexico genome editing market, by application
7.2.2.8. Mexico genome editing market, by technology
7.2.2.9. Mexico genome editing market, by end user
7.2.3. North America market size and forecast, by application
7.2.4. North America market size and forecast, by technology
7.2.4.1. North America CRISPR, by end user
7.2.4.2. North America TALEN, by end user
7.2.4.3. North America ZFN, by end user
7.2.4.4. North America other technologies, by end user
7.2.5. North America market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany genome editing market, by application
7.3.2.2. Germany genome editing market, by technology
7.3.2.3. Germany genome editing market, by end user
7.3.2.4. France genome editing market, by application
7.3.2.5. France genome editing market, by technology
7.3.2.6. France genome editing market, by end user
7.3.2.7. UK genome editing market, by application
7.3.2.8. UK genome editing market, by technology
7.3.2.9. UK genome editing market, by end user
7.3.2.10. Italy genome editing market, by application
7.3.2.11. Italy genome editing market, by technology
7.3.2.12. Italy genome editing market, by end user
7.3.2.13. Spain genome editing market, by application
7.3.2.14. Spain genome editing market, by technology
7.3.2.15. Spain genome editing market, by end user
7.3.2.16. Rest of Europe genome editing market, by application
7.3.2.17. Rest of Europe Genome editing market, by technology
7.3.2.18. Rest of Europe Genome editing market, by end user
7.3.3. Europe market size and forecast, by application
7.3.4. Europe market size and forecast, by technology
7.3.4.1. Europe CRISPR, by end user
7.3.4.2. Europe TALEN, by end user
7.3.4.3. Europe ZFN, by end user
7.3.4.4. Europe other technologies, by end user
7.3.5. Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan Genome editing market, by application
7.4.2.2. Japan Genome editing market, by technology
7.4.2.3. Japan Genome editing market, by end user
7.4.2.4. China Genome editing market, by application
7.4.2.5. China genome editing market, by technology
7.4.2.6. China genome editing market, by end user
7.4.2.7. Australia genome editing market, by application
7.4.2.8. Australia genome editing market, by technology
7.4.2.9. Australia genome editing market, by end user
7.4.2.10. India genome editing market, by application
7.4.2.11. India genome editing market, by technology
7.4.2.12. India genome editing market, by end user
7.4.2.13. South Korea genome editing market, by application
7.4.2.14. South Korea genome editing market, by technology
7.4.2.15. South Korea genome editing market, by end user
7.4.2.16. Rest of Asia-Pacific genome editing market, by application
7.4.2.17. Rest of Asia-Pacific genome editing market, by technology
7.4.2.18. Rest of Asia-Pacific genome editing market, by end user
7.4.3. Asia-Pacific market size and forecast, by application
7.4.4. Asia-Pacific market size and forecast, by technology
7.4.4.1. Asia-Pacific CRISPR, by end user
7.4.4.2. Asia-Pacific TALEN, by end user
7.4.4.3. Asia-Pacific ZFN, by end user
7.4.4.4. Asia-Pacific other technologies, by end user
7.4.5. Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil genome editing market, by application
7.5.2.2. Brazil genome editing market, by technology
7.5.2.3. Brazil genome editing market, by end user
7.5.2.4. Saudi Arabia genome editing market, by application
7.5.2.5. Saudi Arabia genome editing market, by technology
7.5.2.6. Saudi Arabia genome editing market, by end user
7.5.2.7. South Africa genome editing market, by application
7.5.2.8. South Africa genome editing market, by technology
7.5.2.9. South Africa genome editing market, by end user
7.5.2.10. Rest of LAMEA genome editing market, by application
7.5.2.11. Rest of LAMEA genome editing market, by technology
7.5.2.12. Rest of LAMEA genome editing market, by end user
7.5.3. LAMEA market size and forecast, by application
7.5.4. LAMEA market size and forecast, by technology
7.5.4.1. LAMEA CRISPR, by end user
7.5.4.2. LAMEA TALEN, by end user
7.5.4.3. LAMEA ZFN, by end user
7.5.4.4. LAMEA other technologies, by end user
7.5.5. LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. AGLIENT TECHNOLOGIES, INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. CRISPR Therapeutics AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. DANAHER CORPORATION
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. EUROFINS SCIENTIFIC
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. EDITAS MEDICINE, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. GENSCRIPT BIOTECH CORPORATION
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. PERKINELMER, INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. LONZA GROUP LTD.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. MERCK KGAA
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. THERMO FISHER SCIENTIFIC, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developmentLIST OF TABLES
TABLE 01. GENOME EDITING MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 02. CELL LINE ENGINEERING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03. GENETIC ENGINEERING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04. GENE MODIFIED CELL THERAPY AND DIAGNOSTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05. DRUG DISCOVERYMARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06. OTHER APPLICATIONS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07. GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030($MILLION)
TABLE 08. CRISPR MARKET, BY REGION, 2020-2030($MILLION)
TABLE 09. GENOME EDITING MARKET, FOR CRISPR, BY END USER, 2020-2030, ($MILLION)
TABLE 10. TALEN MARKET, BY REGION, 2020-2030($MILLION)
TABLE 11. GENOME EDITING MARKET, FOR TALEN, BY END USER, 2020-2030, ($MILLION)
TABLE 12. ZFN MARKET, BY REGION, 2020-2030($MILLION)
TABLE 13. GENOME EDITING MARKET, FOR ZFN, BY END USER, 2020-2030, ($MILLION)
TABLE 14. OTHER TECHNOLOGIES MARKET, BY REGION, 2020-2030($MILLION)
TABLE 15. GENOME EDITING MARKET, FOR OTHER TECHNOLOGIES, BY END USER, 2020-2030, ($MILLION)
TABLE 16. GENOME EDITING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 17. ACADEMICS & GOVERNMENT INSTITUTES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18. BIOTECHNOLOGY & PHARMA COMPANIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19. CONTRACT RESEARCH ORGANIZATION MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20. GENOME EDITING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 21. NORTH AMERICA GENOME EDITING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 22. U.S. GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 23. U.S. GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 24. U.S. GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 25. CANADA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 26. CANADA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 27. CANADA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 28. MEXICO GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 29. MEXICO GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 30. MEXICO GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 31. NORTH AMERICA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 32. NORTH AMERICA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 33. NORTH AMERICA CRISPR, BY END USER, 2020-2030
TABLE 34. NORTH AMERICA TALEN, BY END USER, 2020-2030
TABLE 35. NORTH AMERICA ZFN, BY END USER, 2020-2030
TABLE 36. NORTH AMERICA OTHER TECHNOLOGIES, BY END USER, 2020-2030
TABLE 37. NORTH AMERICA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 38. EUROPE GENOME EDITING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 39. GERMANY GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 40. GERMANY GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 41. GERMANY GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 42. FRANCE GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 43. FRANCE GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 44. FRANCE GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 45. UK GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 46. UK GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 47. UK GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 48. ITALY GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 49. ITALY GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 50. ITALY GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 51. SPAIN GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 52. SPAIN GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 53. SPAIN GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 54. REST OF EUROPE GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 55. REST OF EUROPE GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 56. REST OF EUROPE GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 57. EUROPE GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 58. EUROPE GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 59. EUROPE HOSPITALS, BY END USER, 2020-2030
TABLE 60. EUROPE TALEN, BY END USER, 2020-2030
TABLE 61. EUROPE ZFN, BY END USER, 2020-2030
TABLE 62. EUROPE OTHER TECHNOLOGIES, BY END USER, 2020-2030
TABLE 63. EUROPE GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 64. ASIA-PACIFIC GENOME EDITING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 65. JAPAN GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 66. JAPAN GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 67. JAPAN GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 68. CHINA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 69. CHINA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 70. CHINA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 71. AUSTRALIA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 72. AUSTRALIA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 73. AUSTRALIA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 74. INDIA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 75. INDIA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 76. INDIA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 77. SOUTH KOREA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 78. SOUTH KOREA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 79. SOUTH KOREAGENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 80. REST OF ASIA-PACIFIC GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 81. REST OF ASIA-PACIFIC GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 82. REST OF ASIA-PACIFIC GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 83. ASIA-PACIFIC GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 84. ASIA-PACIFIC GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 85. ASIA-PACIFIC HOSPITALS, BY END USER, 2020-2030
TABLE 86. EUROPE TALEN, BY END USER, 2020-2030
TABLE 87. ASIA-PACIFIC ZFN, BY END USER, 2020-2030
TABLE 88. ASIA-PACIFIC OTHER TECHNOLOGIES, BY END USER, 2020-2030
TABLE 89. ASIA-PACIFIC GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 90. LAMEA GENOME EDITING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 91. BRAZIL GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 92. BRAZIL GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 93. BRAZIL GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 94. SAUDI ARABIA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 95. SAUDI ARABIA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 96. SAUDI ARABIA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 97. SOUTH AFRICA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 98. SOUTH AFRICA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 99. SOUTH AFRICA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 100. REST OF LAMEA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 101. REST OF LAMEA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 102. REST OF LAMEA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 103. LAMEA GENOME EDITING MARKET, BY APPLICATION, 2020-2030
TABLE 104. LAMEA GENOME EDITING MARKET, BY TECHNOLOGY, 2020-2030
TABLE 105. LAMEA CRISPR, BY END USER, 2020-2030
TABLE 106. LAMEA TALEN, BY END USER, 2020-2030
TABLE 107. LAMEA ZFN, BY END USER, 2020-2030
TABLE 108. LAMEA OTHER TECHNOLOGIES, BY END USER, 2020-2030
TABLE 109. LAMEA GENOME EDITING MARKET, BY END USER, 2020-2030
TABLE 110. AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 111. AGILENT TECHNOLOGIES: OPERATING SEGMENTS
TABLE 112. AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 113. AGILENT TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. CRISPR THERAPEUTICS: COMPANY SNAPSHOT
TABLE 115. CRISPR THERAPEUTICS: OPERATING SEGMENTS
TABLE 116. CRISPR THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 117. CRISPR THERAPEUTICS: KEY DEVELOPMENTS
TABLE 118. DANAHER: COMPANY SNAPSHOT
TABLE 119. DANAHER: PRODUCT SEGMENTS
TABLE 120. DANAHER: PRODUCT PORTFOLIO
TABLE 121. DANAHER: KEY DEVELOPMENTS
TABLE 122. EUROFINS: COMPANY SNAPSHOT
TABLE 123. EUROFINS: PRODUCT PORTFOLIO
TABLE 124. EUROFINS: KEY DEVELOPMENTS
TABLE 125. EDITAS MEDICINE: COMPANY SNAPSHOT
TABLE 126. EDITAS MEDICINE: OPERATING BUSINESS SEGMENTS
TABLE 127. EDITAS MEDICINE: PRODUCT PORTFOLIO
TABLE 128. EDITAS MEDICINE: KEY DEVELOPMENTS
TABLE 129. GENSCRIPT: COMPANY SNAPSHOT
TABLE 130. GENSCRIPT: OPERATING SEGMENTS
TABLE 131. GENSCRIPT: PRODUCT PORTFOLIO
TABLE 132. GENSCRIPT: KEY DEVELOPMENTS
TABLE 133. PERKINELMER: COMPANY SNAPSHOT
TABLE 134. PERKINELMER: OPERATING SEGMENTS
TABLE 135. PERKINELMER: PRODUCT PORTFOLIO
TABLE 136. PERKINELMER : KEY DEVELOPMENTS
TABLE 137. LONZA: COMPANY SNAPSHOT
TABLE 138. LONZA: OPERATING SEGMENTS
TABLE 139. LONZA: PRODUCT PORTFOLIO
TABLE 140. LONZA: KEY DEVELOPMENTS
TABLE 141. MERCK: COMPANY SNAPSHOT
TABLE 142. MERCK: OPERATING SEGMENTS
TABLE 143. MERCK: PRODUCT PORTFOLIO
TABLE 144. MERCK: KEY DEVELOPMENTS
TABLE 145. THERMO FISHER: COMPANY SNAPSHOT
TABLE 146. THERMO FISHER: OPERATING SEGMENTS
TABLE 147. THERMO FISHER: PRODUCT PORTFOLIO
TABLE 148. THERMO FISHER: KEY DEVELOPMENTSLIST OF FIGURES
FIGURE 01. GENOME EDITING MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF GENETIC ENGINEERINGMARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF GENETIC ENGINEERING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF GENE MODIFIED CELL THERAPY AND DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF DRUG DISCOVERY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF OTHER APPLICATIONS MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF CRISPR MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19. ACADEMICS & GOVERNMENT INSTITUTES MARKET, 2020-2030, ($MILLION)
FIGURE 20. BIOTECHNOLOGY & PHARMA COMPANIES MARKET, 2020-2030, ($MILLION)
FIGURE 21. CONTRACT RESEARCH ORGANIZATIONS MARKET, 2020-2030, ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF TALEN MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23. ACADEMICS & GOVERNMENT INSTITUTES MARKET, 2020-2030, ($MILLION)
FIGURE 24. BIOTECHNOLOGY & PHARMA COMPANIES MARKET, 2020-2030, ($MILLION)
FIGURE 25. CONTRACT RESEARCH ORGANIZATION MARKET, 2020-2030, ($MILLION)
FIGURE 26. COMPARATIVE ANALYSIS OF ZFN MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27. ACADEMICS & GOVERNMENT INSTITUTES MARKET, 2020-2030, ($MILLION)
FIGURE 28. BIOTECHNOLOGY & PHARMA COMPANIES MARKET, 2020-2030, ($MILLION)
FIGURE 29. CONTRACT RESEARCH ORGANIZATIONS MARKET, 2020-2030, ($MILLION)
FIGURE 30. COMPARATIVE ANALYSIS OF OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 31. ACADEMICS & GOVERNMENT INSTITUTES MARKET, 2020-2030, ($MILLION)
FIGURE 32. PHARMACEUTICAL COMPANIES MARKET, 2020-2030, ($MILLION)
FIGURE 33. CONTRACT RESEARCH ORGANIZATIONS MARKET, 2020-2030, ($MILLION)
FIGURE 34. COMPARATIVE ANALYSIS OF ACADEMICS & GOVERNMENT INSTITUTES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 35. COMPARATIVE ANALYSIS OF BIOTECHNOLOGY & PHARMA COMPANIES GENOME EDITING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 36. COMPARATIVE ANALYSIS OF CONTRACT RESEARCH ORGANIZATION MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 01. AGILENT TECHNOLOGIES: NET SALES, 2018-2020 ($MILLION)
FIGURE 02. AGILENT TECHNOLOGIES: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 03. AGILENT TECHNOLOGIES: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 04. CRISPR THERAPEUTICS: NET SALES, 2017-2019 ($MILLION)
FIGURE 05. DANAHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 06. DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 07. DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 08. EUROFINS: NET SALES, 2018-2020 ($MILLION)
FIGURE 09. EUROFINS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 10. GENSCRIPT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 11. GENSCRIPT: REVENUE SHARE BY REGION, 2020(%)
FIGURE 12. PERKINELMER: NET SALES, 2018-2020 ($MILLION)
FIGURE 13. PERKINELMER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 14. PERKINELMER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 15. LONZA: NET SALES, 2018-2020 ($MILLION)
FIGURE 16. LONZA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 17. LONZA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 18. MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 19. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20. MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21. THERMO FISHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 22. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23. THERMO FISHER: REVENUE SHARE BY REGION, 2020(%)
Companies Mentioned
- Agilent Technologies
- CRISPR Therapeutics
- Danaher
- Eurofins Scientific
- Editas Medicine
- GenScript
- Horizon Discovery Limited
- Lonza
- Merck Thermo Fisher Scientific.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
